• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Gamida doses first subject in Phase I/II cell therapy trial for lymphomas

cafead

Administrator
Staff member
  • cafead   Aug 11, 2022 at 12:22: PM
via Gamida Cell has dosed the first subject in the Phase I/II clinical trial of natural killer (NK) cell therapy candidate GDA-201 to treat patients with follicular and diffuse large B cell lymphomas (FL and DLBCL).

article source